Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP2 antibody-drug conjugate BL-M02D1

An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-TROP2 ADC BL-M02D1, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TROP2-expressing tumor cells, through an as of yet unknown mechanism of action. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TROP2 ADC BL-M02D1
Code name:BL M02D1
BL-M02D1
BLM02D1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search